Apr 13, 2022 / 12:00PM GMT
Gil Blum - Needham & Company, LLC - Analyst
Good morning, and welcome to day 3 of the annual Needham & Company healthcare conference. My name is Gil Blum, and I am a senior biotech analyst here at Needham & Company, covering immuno-oncology and gene therapy subsectors. It is my pleasure to have with me this morning Jeff Trigilio, Chief Financial Officer for Cullinan Oncology. (Conference Instructions)
And with that, Jeff, you have the floor.
Jeff Trigilio - Cullinan Oncology, Inc. - CFO
Thanks, Gil, and thanks for the Needham organization for the support. Excited to talk about Cullinan today. Before I jump in, just a quick note that we'll be making forward-looking statements. Obviously, there's risk with these statements and uncertainty as to what will transpire. We would refer you to the 10-K and 10-Q filings in the SEC website to learn more about the risks of investing in our securities.
So let me start off on slide 3 by giving a couple of highlights on Cullinan. First and foremost is we are one of the broadest and deepest
Cullinan Oncology Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 13, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers